The global digital pathology market is projected to reach USD 756.1 Million by 2022 from USD 423.1 Million in 2017, at a CAGR of 12.3%.
On the basis of product, the market is categorized into scanners, software, communication systems, and storage systems. The software segment is projected to witness the highest growth rate in the forecast period, due to the availability of user-friendly, analytical, and advanced functions for pathology diagnosis.
On the basis of type, the digital pathology market is segmented into human and veterinary pathology. The human pathology segment is expected to account for the largest share of the market in 2017. The increasing number of cancer research activities and growing collaborations between academic research institutes, universities, and pathology laboratories are driving the increased uptake of digital systems in human pathology.
Drivers
1 Increasing Adoption of Digital Pathology to Enhance Lab Efficiency
2 Rising Prevalence of Cancer
3 Growing Applications of Digital Pathology in Drug Development and Companion Diagnostics
4 Ease of Consultation Enabled By Digital Pathology
5 Increasing Initiatives By Governments and Industry Players
PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=844
Restraints
1 High Cost of Digital Pathology Systems
Opportunities
1 Overcoming the Shortage of Pathologists Through Digital Pathology
2 Introduction of Affordable Scanners for Private Pathology Practices
3 Personalized Medicine
4 Integration of Laboratory Information Systems (LIS) and Digital Pathology Systems
The prominent players in the global digital pathology market are Leica Biosystems (Germany), Ventana Medical Systems (US), Hamamatsu Photonics (Japan), 3DHISTECH (Hungary), Philips (Netherlands), Apollo Enterprise Imaging (US), XIFIN (US), Visiopharm (Denmark), Corista (US), Huron Digital Pathology (Canada), Objective Pathology Services (Canada), and Indica Labs (US).
